Advances and difficulties associated with the therapy of chronic HCV infection
Authors:
P. Chalupa; H. Rozsypal
Authors‘ workplace:
Přednosta: doc. MUDr. Hanuš Rozsypal, CSc.
; 1. lékařská fakulta a Nemocnice Na Bulovce
; Klinika infekčních a tropických nemocí
; Univerzita Karlova v Praze
Published in:
Prakt. Lék. 2018; 98(6): 246-252
Category:
Reviews
Overview
The most important aspects associated with the therapy of chronic hepatitis C viral infection (HCV) using interferon-free therapy with DAA drugs (IFN-free DAA regimens) are mentioned. This therapy is very effective, safe, with minimum contraindications and adverse events. We must also permanently remember some crucial principles associated with this therapy: interaction with other medicaments, possibility of HBV reactivation and principles of care after successful treatment.
KEYWORDS:
HCV infection – HBV infection – interferon-free therapy – DAA drugs – HBV reactivation
Sources
1. Belperio PS, Shahoumian TA, Mole LA, et al. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals. Hepatology 2017; 66(1): 27–36.
2. Cacoub P, Comarmond C, Domont F, et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis 2016; 3(1): 3–14.
3. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48(5): 835–847.
4. Dostálek M. Enzymatický systém cytochromu P450. Postgrad Med 2006; 8(1): 46–54.
5. European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67(2): 370–398.
6. European Association for the Study of the Liver. EASL Recommendation on treatment of hepatitis C 2018. J Hepatol 2018, 69(2): 461–511.
7. Hůlek P, Urbánek P, a kol. Hepatologie. Praha: Grada Publishing 2018.
8. Chlíbek R, Smetana J, Šošovičková R, a kol. Výsledky séroprevalenční studie HCV infekce u dospělých v ČR. Hradecké virologické dny, Hradec Králové, 12.–13. 10. 2016 [online]. Dostupné z: https//www.fnhk.cz/fs1899/15chlibekprevalencehcvv-cr.pdf [cit. 2018-09-30].
9. Mastera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128(2): 343–350.
10. Sherman AC, Sherman KE. Extrahepatic manifestations of hepatitis C infection: navigating CHASM. Curr HIV/AIDS Rep 2015; 12(3): 353–361.
11. Suchopár J, Prokeš M. Přímo působící antivirotika proti hepatitidě typu C a jejich lékové interakce. Remedia 2018; 28(1): 95–108.
12. Urbánek P, Husa P, Šperl J, a kol. Standardní diagnostický a terapeutický postup chronické infekce virem hepatitidy C (HCV). Klin Mikrobiol Infekc Lek 2017; 23(1): 22–40.
Labels
General practitioner for children and adolescents General practitioner for adultsArticle was published in
General Practitioner
2018 Issue 6
Most read in this issue
- Dark lesions in the oral cavity – differential diagnosis
- Surrogacy in the Czech Republic: current status and the responsibility of the general practicioner
- Use of telerehabilitation as a complement to regular rehabilitation care
- Analysis of the most common food-and water-borne diseases in the Czech Republic, 2007–2017